Bottom line
Is GTHIX a good fund? The bottom line
GTHIX is the Investor Class share class of INVESCO Health Care Fund, a managed health care sector mutual fund from Invesco.
Its expense ratio is 1.07% — about $107 a year on every $10,000 invested, more expensive than 62% of health care sector funds we track.
It returned +15.5% over one year, +3.7% a year over five years, +6.4% a year over ten (as of Dec 31, 2025, per its prospectus).
With $1.2 billion in net assets and 82 holdings, its largest position is Eli Lilly and Co. (10.6%) and the top 10 make up 48.5% of the portfolio.
The closest lower-cost alternative we found is XLV (0.08%, 55% top-holdings overlap).
What stands out
- No front-end sales load
What to watch
- 12b-1 marketing fee of 0.25% a year
Updated Nov 19, 2026
What GTHIX invests in
The Funds investment objective is long-term growth of capital.
The Fund invests, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of issuers engaged primarily in health care-related industries, and in derivatives and other instruments that have economic characteristics similar to such securities. The Fund will concentrate its investments in the securities of domestic and foreign issuers in the health care industry. The Fund uses various criteria to determine whether an issuer is engaged in health care-related industries, including whether (1) it derives 50% or more of its gross income or its net sales from activities in the health care industry; (2) it devotes 50% or more of its assets to producing revenues from the health care industry; or (3) based on other available information, the Funds portfolio managers determine that its primary business is within the health care…
From the fund's prospectus (filed Feb 27, 2026).
GTHIX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| GTHIX | +15.5% | +3.7% | +6.4% |
| Health Care Sector median | +14.5% | +4.2% | +7.9% |
Source: Fund prospectus, as of Dec 31, 2025
What GTHIX costs
On a $10,000 investment, GTHIX's 1.07% expense ratio costs about $107 a year. The prospectus estimates $1,306 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.
GTHIX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Eli Lilly and Co. | 10.59% |
| 2 | Johnson & Johnson | 6.76% |
| 3 | UnitedHealth Group Inc. | 6.17% |
| 4 | Invesco Private Prime Fund | 4.67% |
| 5 | Merck & Co., Inc. | 4.59% |
| 6 | AbbVie Inc. | 4.03% |
| 7 | Gilead Sciences, Inc. | 3.63% |
| 8 | argenx SE | 3.24% |
| 9 | CVS Health Corp. | 2.52% |
| 10 | Welltower Inc. | 2.34% |
Source: SEC Form N-PORT, period ended Jul 31, 2026
The top 10 make up 48.5% of the fund. See all top 25 holdings and asset mix →
Alternatives to GTHIX
| Family | Fund | Expense ratio | Overlap | |
|---|---|---|---|---|
| SPDR (State Street) | XLV State Street(R) Health Care Select… | 0.08% | 55% | Compare |
| Fidelity | FHLC Fidelity MSCI Health Care Index ETF | 0.084% | 54% | Compare |
| Vanguard | VHT Vanguard Health Care Index Fund | 0.09% | 54% | Compare |
| iShares | IYH iShares U.S. Healthcare ETF | 0.37% | 52% | Compare |
| Schwab | SWHFX Schwab Health Care Fund | 0.8% | 51% | Compare |
| T. Rowe Price | PRHSX T. Rowe Price Health Sciences Fund, Inc. | 0.83% | 59% | Compare |